Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Antidepressant for the prevention of depression following first episode psychosis (ADDEP Trial)
2020-002787-32Phase 3Unknown
- Sponsor
- University of Birmingham
- Start
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in major depressive disorder (MDD) and psychosis comparing Sertraline with Placebo (2 arms). Primary endpoint: Incidence of new depressive episodes over 6 months. Status: unknown.
02
Drugs
sertraline
03
Conditions
major depressive disorder (MDD)psychosis
Beyond the preview
Go deeper on 2020-002787-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002787-32.